We Know How To Prescribe Natalizumab For Multiple Sclerosis, But Do We Know How To Withdraw It?

dc.creatorFragoso Y.D.
dc.creatorArruda N.M.
dc.creatorArruda W.O.
dc.creatorBrooks J.B.B.
dc.creatorCorrea E.C.
dc.creatorDamasceno A.
dc.creatorDamasceno C.A.
dc.creatorFerreira M.L.B.
dc.creatorGiacomo M.C.B.
dc.creatorGomes S.
dc.creatorGoncalves M.V.M.
dc.creatorGrzesiuk A.K.
dc.creatorKaimen-Maciel D.R.
dc.creatorLopes J.
dc.creatorMachado S.C.N.
dc.creatorOliveira C.L.S.
dc.creatorStella C.R.A.V.
dc.date2014
dc.date2015-06-25T17:52:31Z
dc.date2015-11-26T14:17:18Z
dc.date2015-06-25T17:52:31Z
dc.date2015-11-26T14:17:18Z
dc.date.accessioned2018-03-28T21:18:22Z
dc.date.available2018-03-28T21:18:22Z
dc.identifier
dc.identifierExpert Review Of Neurotherapeutics. , v. 14, n. 2, p. 127 - 130, 2014.
dc.identifier14737175
dc.identifier10.1586/14737175.2014.874947
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84893060675&partnerID=40&md5=def18976aa18d4765c17f7a3611f2bf6
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/86289
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/86289
dc.identifier2-s2.0-84893060675
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1243297
dc.descriptionNatalizumab is a potent immunosuppressive monoclonal antibody used for the treatment of multiple sclerosis (MS). While definite guidelines for the safety of natalizumab prescriptions are available in all countries, there are no specific recommendations on how to withdraw the drug if the need arises. There are reports describing MS complications after natalizumab infusions were stopped. Most neurologists seem to stop natalizumab treatment according to their idea on how to best carry out the withdrawal. The present study shows the very different manners in which expert neurologists from 14 MS units in Brazil stopped natalizumab in their patients. The authors concluded that pharmacovigilance on natalizumab must persist after the drug is withdrawn in order to have enough data for adequate recommendations. © 2014 Informa UK, Ltd.
dc.description14
dc.description2
dc.description127
dc.description130
dc.descriptionNylander, A., Hafler, D.A., Multiple sclerosis (2012) J Clin Invest, 122, pp. 1180-1188
dc.descriptionMcCoyd, M., Update on therapeutic options for multiple sclerosis (2013) Neurol Clin, 31, pp. 827-845
dc.descriptionMcCormack, P.L., Natalizumab: A review of its use in the management of relapsing-remitting multiple sclerosis (2013) Drugs, 73 (13), pp. 1463-1481
dc.descriptionFernández, O., Best practice in the use of natalizumab in multiple sclerosis (2013) Ther Adv Neurol Disord, 6, pp. 69-79
dc.descriptionSørensen, P.S., Bertolotto, A., Edan, G., Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (2012) Mult Scler, 18, pp. 143-152
dc.descriptionPucci, E., Giuliani, G., Solari, A., Natalizumab for relapsing remitting multiple sclerosis (2011) Cochrane Database Syst Rev, 10, pp. CD007621
dc.descriptionFragoso, Y.D., Alves-Leon, S.V., Arruda, W.O., Natalizumab adverse events are rare in patients with multiple sclerosis (2013) Arq Neuropsiquiatr, 71, pp. 137-141
dc.descriptionDamasceno, A., Von Glehn, F., Martinez, A.R., Early onset of natalizumab-related progressive multifocal leukoencephalopathy (2011) Mult Scler, 17, pp. 1397-1398
dc.descriptionBaumgartner, A., Stich, O., Rauer, S., Clinical and radiological disease reactivation after cessation of long-Term therapy with natalizumab (2012) Int J Neurosci, 122, pp. 35-39
dc.descriptionRigau, V., Mania, A., Béfort, P., Lethal multiple sclerosis relapse after natalizumab withdrawal (2012) Neurology, 79, pp. 2214-2216
dc.descriptionMarousi, S., Travasarou, M., Karageorgiou, C.E., Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS (2012) Neurology, 79, p. 2160
dc.descriptionBerger, J.R., Centonze, D., Comi, G., Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) Ann Neurol, 68, pp. 409-411
dc.descriptionMiravalle, A., Jensen, R., Kinkel, R.P., Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy (2011) Arch Neurol, 68, pp. 186-191
dc.descriptionBorriello, G., Prosperini, L., Marinelli, F., Observations during an elective interruption of natalizumab treatment: A post-marketing study (2011) Mult Scler, 17, pp. 372-375
dc.descriptionPapeix, C., Depaz, R., Tourbah, A., Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse (2011) Mult Scler, 17, pp. 1520-1522
dc.descriptionBorriello, G., Prosperini, L., Mancinelli, C., Pulse monthly steroids during an elective interruption of natalizumab: A post-marketing study (2012) Eur J Neurol, 19, pp. 783-787
dc.descriptionMagraner, M.J., Coret, F., Navarré, A., Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study (2011) J Neurol, 258, pp. 1805-1811
dc.descriptionRossi, S., Motta, C., Studer, V., Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab (2013) Eur J Neurol, 20, pp. 87-94
dc.descriptionHavla, J., Gerdes, L.A., Meinl, I., De-escalation from natalizumab in multiple sclerosis: Recurrence of disease activity despite switching to glatiramer acetate (2011) J Neurol, 258, pp. 1665-1669
dc.descriptionGobbi, C., Meier, D.S., Cotton, F., Interferon beta 1b following natalizumab discontinuation: One year, randomized, prospective, pilot trial (2013) BMC Neurol, 13, p. 101
dc.descriptionCree, B., De Seze, J., Fox, R., RESTORE Study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity 2012
dc.descriptionP06.168 (2012) Neurology, (78), pp. 106-168. , Meeting Abstracts 1
dc.descriptionComi, G., Gold, R., Dahlke, F., Overall safety and relapse outcomes in fingolimod-Treated patients previously treated with natalizumab in the 4-month open-label first study [poster (2013) European Neurology Society (ENS) Meeting Barcelona Spain
dc.descriptionHavla, J., Tackenberg, B., Hellwig, K., Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis (2013) J Neurol, 260, pp. 1382-1387
dc.descriptionDaelman, L., Maitrot, A., Maarouf, A., Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal (2012) Mult Scler, 11, pp. 1647-1649
dc.descriptionSempere, A.P., Martín-Medina, P., Berenguer-Ruiz, L., Switching from natalizumab to fingolimod: An observational study (2013) Acta Neurol Scand, 128, pp. e6-e10
dc.descriptionCentonze, D., Rossi, S., Rinaldi, F., Gallo, P., Severe relapses under fingolimod treatment prescribed after natalizumab (2012) Neurology, 79, pp. 2004-2005
dc.descriptionJander, S., Turowski, B., Kieseier, B.C., Hartung, H.P., Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod (2012) Mult Scler, 18, pp. 1650-1652
dc.languageen
dc.publisher
dc.relationExpert Review of Neurotherapeutics
dc.rightsfechado
dc.sourceScopus
dc.titleWe Know How To Prescribe Natalizumab For Multiple Sclerosis, But Do We Know How To Withdraw It?
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución